decades of Experience
A pioneering legacy that continues to positively impact patients
"The essence of research is to find something for which there is no answer and then have the guts to try to find the answer."
Michael B. Sporn, MD
Founder
1933-2022
A career dedicated to improving patient outcomes through research, discovery, and design of innovative therapeutics.
A Distinguished Career:
31 years at NIH/NCI that included positions as Chief of the Lung Cancer Branch and Chief of the Laboratory of Chemoprevention;
20 years as Professor of Pharmacology and Medicine at Dartmouth Medical School
Founder of Triterpenoid Therapeutics, Inc.
Significant Accomplishments:
Established the field of Retinoids and the foundational science for Tretinoin
Named “Father of Chemoprevention” by National Foundation for Cancer Research (NFCR)
Discovered TGF-β, a major target in cancer and immune disease
Discoverer and Developer of CDDO, Bardoxolone-Methyl and numerous new synthetic triterpenoid drugs
Author of over 500 peer reviewed journal articles
Awards and Acknowledgements
American Cancer Society Medal of Honor
Bristol Meyers Squibb Award for Distinguished Achievement in Cancer Research
Susan G. Komen Breast Cancer Foundation Brinker Award
American Association of Cancer Research Award for Excellence in Cancer Prevention Research
National Cancer Institute Eminent Scholar
